FAVARETTO, A.; GROSSI, F.; MORABITO, A.; RAVASIO, R. Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations: Il Costo Degli Eventi Avversi Associati ad Afatinib, Erlotinib e Gefitinib Nel Trattamento del Tumore del Polmone non a Piccole Cellule con Mutazione EGFR. Global and Regional Health Technology Assessment, [S. l.], v. 4, n. 1, p. 187–196, 2017. DOI: 10.33393/grhta.2017.394. Disponível em: https://journals.aboutscience.eu/index.php/grhta/article/view/394. Acesso em: 24 may. 2024.